Trial Profile

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2021 Results published in an Aptinyx Media Release.
15 Jun 2021 According to an Aptinyx media release, In the process of completing its in-depth data analysis to prepare for and finalize the design of the Phase 2b program, the company identified a statistical modeling error made by the CRO that performed the statistical analysis in this study. The CRO confirmed the error in late May and reported the updated statistical analysis to the company in June.
29 Apr 2021 Primary endpoint (CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores at 50mg dose) has been met, according to an Aptinyx media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com